CSOP Hang Seng Biotech ETF (03174.HK) Rises 2.60%, Turnover Reaches HKD 9.0653 Million
Newtimespace News: As of 11:42 on August 13, CSOP Hang Seng Biotech ETF (03174.HK) stood at HKD 3.792, up 2.60%. The ETF opened at HKD 3.698, with the latest net asset value (NAV) at HKD 3.697, a discount of 0.03%, a 52-week high of HKD 4.456, a 52-week low of HKD 2.780, a turnover of approximately HKD 9.0653 million, and assets under management of approximately HKD 939 million.
CSOP Hang Seng Biotech ETF (03174.HK) closely tracks the Hang Seng Biotech Index. The manager of the fund is CSOP Asset Management Limited. The investment objective of the Sub-Fund is to provide investment results closely tracking the performance of the Index (i.e., the Hang Seng Biotech Index) (the "Index") before deduction of fees and expenses.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSOP Biotech(03174.HK) up 3.22%, Hengrui Novo license up to $2.6bn
- HK shares ETFs Daily Report: ChinaAMC Innovative Drugs Leads Gains; Biotech and Semiconductors Strengthen, Hang Seng TECH Retreats — September 29, 2026
- CSOP Biotech(03174.HK) up 2.89%, AstraZeneca $2bn Akeso partner deal
- CSOP Hang Seng Biotech ETF (03174.HK) Rises 4.84% Intraday after Ten Departments Issue the Pharmaceutical Industry 15th Five-Year Plan, Targeting 20%+ Annual Growth for Innovative Drugs
- CSOP Hang Seng Biotech ETF (03174.HK) up 4.79% intraday on policy catalysts